V-122 Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315

Hintergrund

CRISP is a non-interventional, prospective, multi-center clinical research platform whose aim is to understand the treatment reality of patients (pts) with lung carcinoma in Germany. Here we present first data of pts diagnosed with NSCLC in stages II or III (IIIB/C if treated with curative intent).

 

Scroll to top

Material und Methode

Between August 2018 and February 2020 around 100 sites in Germany recruited more than 800 pts diagnosed with NSCLC stage II/III. Basic demographic data, details about treatment reality, outcome and PRO data are collected and analyzed. Here we present first data on 715 pts followed until 30 June 2020.

 

Scroll to top

Ergebnis

25% of the pts were diagnosed with stage II (4% in stage IIA, 21% in stage IIB), and 68% with stage III disease (33% in stage IIIA, 34% in stage IIB/C).

The median age at primary diagnosis was 65 years (38% women, 62% men), 47% of the pts had a very good overall condition at diagnosis (ECOG=0). 80% of the pts presented with comorbidities; 47% had a Charlson comorbidity index of 0.

Most of the pts with tumors in stage II underwent surgery (84%, n=153) followed by adjuvant chemotherapy (CTx) (currently 67%, n=123). For pts with stage IIIA tumors the most frequent sequence of treatment was also surgery (56%, n=134) followed by adjuvant CTx (currently 37%, n=89). 24% (n=57) of the pts with stage IIIA received radiochemotherapy (RTCTx). For pts with stage IIIB/C tumors the most frequent treatment was RTCTx (n=101, 41%); 35% (n=85) started with CTx, and 20% (n=50) had surgery [AA1] (followed mostly by CTx, currently n=35, 14%).

Surgery was performed in 97% (n=30) of the pts with a stage IIA tumor, 86% (n=130) in stage IIB, 66% (n=157) in stage IIIA and 29% (n=70) in stage IIIB/C. 70% of all the surgeries performed were thoracotomies. Video- or robotic- assisted thoracotomies were performed in about 20% of the cases. 48% (n=201) of the pts had a lobectomy, and 14% (n=57) a pneumonectomy. Extended resections were done in 20% (n=81) of all operations. An extended lymphadenectomy was performed in 78% (n=328) of the procedures, with 74% of them being a systematic mediastinal lymphadenectomy.

90% of the procedures overall were R0 resections. Almost all pts receiving adjuvant CTx after resection were treated with vinorelbine (92%, n=252); 74% (n=203) were treated with cisplatin.

 

Scroll to top

Schlussfolgerung

CRISP presents comprehensive current real-life data of patients with NSCLC in stage II or III covering all treatment settings in Germany. With longer follow-up outcome in routine care will be analyzed.

 

Scroll to top

 

Scroll to top

Publikationsverlauf

Artikel online veröffentlicht:
06. September 2021